By activating the RIG-I pathway, the proliferation and metastasis of tumor cells can be inhibited, the tumor immune microenvironment can be improved, and the anti-tumor immune response can be enhanced, which provides new strategies and directions for the treatment of lung cancer (Figure 4). Here, RIGI is linked to lung cancer.